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Hematologic responses to hypomethylating agents are oftendelayed in patients with myelodysplastic syndrome or acutemyeloid leukemia. Fetal hemoglobin is a potential novel bio-
marker of response: recently, we demonstrated that a high fetal hemo-
globin level prior to decitabine treatment was associated with superior
outcome. Here we investigated whether early fetal hemoglobin induc-
tion during decitabine treatment also had prognostic value, and studied
the potential of decitabine to induce erythroid differentiation and fetal
hemoglobin expression in vitro. Fetal hemoglobin levels were measured
by high-performance liquid chromatography in patients with higher-risk
myelodysplastic syndrome (n=16) and acute myeloid leukemia (n=37)
before treatment and after each course of decitabine. Levels above 1.0%
were considered induced. Patients achieving complete or partial remis-
sion as best response had attained a median fetal hemoglobin of 1.9%
after two courses of treatment, whereas the median value in patients
who did not reach complete or partial remission was 0.8% (P=0.015).
Fetal hemoglobin induction after two courses of decitabine treatment
was associated with early platelet doubling (P=0.006), and its subsequent
decrease with hematologic relapse. In patients with myelodysplastic
syndrome, induction of fetal hemoglobin after course 2 of treatment was
associated with longer overall survival: median of 22.9 versus 7.3 months
in patients with or without induction of fetal hemoglobin, respectively
[hazard ratio=0.2 (95% confidence interval: 0.1-0.9); P=0.03]. In vitro
decitabine treatment of two bi-potential myeloid leukemia cell lines
(K562 and HEL) resulted in induction of an erythroid (not megakaryocyt-
ic) differentiation program, and of fetal hemoglobin mRNA and protein,
associated with GATA1 gene demethylation and upregulation. In conclu-
sion, fetal hemoglobin may provide a useful dynamic biomarker during
hypomethylating agent therapy in patients with myelodysplastic syn-
drome or acute myeloid leukemia. 
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DNA-hypomethylating agents (HMAs) alter gene
expression of malignant cells by gene reactivation, e.g. of
epigenetically silenced tumor suppressor genes resulting
in induction of apoptosis or senescence,1-4 or of
cancer/testis antigens and retroviral sequences, thus elic-
iting an immune response against cancer cells,5,6 and by
reduction of oncogene overexpression.7 In cell line models
of acute myeloid leukemia (AML), they also induce gran-
ulocytic maturation although this effect has yet to be val-
idated in vivo.8
Probably the earliest proof of therapeutic gene reactiva-
tion by an HMA was the demonstration of induction of
fetal hemoglobin (HbF) in a patient with severe beta-tha-
lassemia through demethylation and transcriptional acti-
vation of the gamma-globin gene locus,9 the developmen-
tal regulation of which is governed by DNA methylation.
This ability of HMAs to de-repress epigenetically silenced
gamma-globin expression in (polyclonal) erythropoietic
precursors has also been observed in patients with solid
tumors10,11 and has prompted clinical trials on the use of
HMAs in hemoglobinopathies.12,13
Several groups have shown that in patients with
myelodysplastic syndrome (MDS) or AML receiving azac-
itidine, HbF is induced and may be a marker of treatment
effect.14,15 Very recently, we observed elevated HbF levels
also in MDS/AML patients treated with decitabine.16 We
now dissected the kinetics of the in vivo induction of HbF
in these patients with high-risk MDS or AML, in order to
evaluate the prognostic value of HbF induction. We
observed that HbF levels after two courses of treatment
were of prognostic value regarding hematologic responses
of the different lineages, and, in MDS, for overall survival
from this time point on [hazard ratio (HR)=0.2; 95% con-
fidence interval (95% CI): 0.1-0.9; P=0.03]. The cellular
source of HbF in responders appeared to be predominant-
ly non-malignant erythroid precursors. To model HbF
reactivation in vitro, we investigated two transformed
leukemia cell lines for the induction of an erythroid differ-
entiation program that also encompassed HbF protein
synthesis induced by decitabine. 
Methods
Patients, treatments and response evaluations
Details on the patients, the treatments given and evaluation of
responses are provided in the Online Supplement. Both the thera-
peutic studies and the translational investigations were
approved by the institutional review board (ethics committee) of
the University of Freiburg Medical Center. Patients (all treated at
the Freiburg study site) provided their written informed consent
to be included in the respective clinical studies, and to related
translational investigations according to the Declaration of
Helsinki.  
Hemoglobin quantification by high-performance liquid
chromatography
HbF levels were measured by high-performance liquid chro-
matography (HPLC) before treatment and after the end of each
treatment course (every 6 weeks) as described previously.17
Patients were grouped by normal (HbF ≤1%) or elevated HbF
levels (HbF >1%), in accordance with reference values for the
University of Freiburg Medical Center Central Laboratory.
Statistical methods
We used non-parametric Spearman correlation coefficients (rs)
to assess the association between HbF levels and other variables.
To address the hypothesis that HbF after course 2 of decitabine
treatment may predict hematologic responses after course 4, we
employed linear regression models with HbF levels as the inde-
pendent variable, and platelet count, hemoglobin concentration,
neutrophil counts, and bone marrow blasts as dependent vari-
ables. Results are displayed graphically. The evaluation of possible
outliers was based on studentized residuals.18 No potential outliers
were excluded from the statistical analyses. The HbF value distri-
butions between responders and non-responders were compared
using the Wilcoxon two-sample test. Before-after differences in
binary variables such as elevated HbF (yes/no) were assessed stat-
ically using the McNemar test.
Time-to-event endpoints comprised overall survival, progres-
sion-free survival, and AML-free survival. We performed land-
mark analyses starting at the time of HbF measurements after two
cycles of decitabine treatment in order to avoid the so-called
immortal-time bias.19 Thus, they were relevant only for patients
who reached this time point. The Kaplan-Meier method was used
to estimate distributions of overall, progression-free and AML-free
survival according to HbF value (> versus ≤1%), and to compute
median estimations. A log-rank test was used to assess the prog-
nostic importance of HbF value, and a Cox model to estimate the
hazard ratio (HR) and its 95% confidence interval (95% CI).
Statistical analyses (all conducted at the CTU Freiburg,
Germany) were performed with SAS 9.2 (SAS Institute Inc., Cary,
NC, USA), and IBM SPSS Statistics 22.
Cell lines and in vitro treatment
K562 and HEL cells (DMSZ, Braunschweig, Germany) were cul-
tured in RPMI1640 containing 10% heat-inactivated fetal calf
serum. Cells were treated with three 24-h pulses of 100 and 20 nM
decitabine (Sigma Aldrich) and harvested 144 h after the first treat-
ment, as described previously.20 Hemin (Sigma Aldrich), a positive
control for induction of erythroid differentiation,21 was added to
the culture medium at a final concentration of 50 mM.22 Cell viabil-
ity was tested by 0.4% trypan blue staining. Megakaryocytic dif-
ferentiation was induced by exposure to 5 nM phorbol ester
(PMA, Sigma Aldrich) for 48 h, as described previously.23 . 
Further information on the methods, including transcriptome
profiling, immunoblotting, and methyl-CpG immunoprecipitation
sequencing, is provided in the Online Supplement.
Results
Kinetics of in vivo induction of HbF in patients with
myelodysplastic syndrome/acute myeloid leukemia
receiving decitabine 
In 40 patients (15 with higher-risk MDS, 25 with AML),
HbF was measured serially twice or more during treat-
ment (in a single patient, HbF before treatment was not
available). The patients’ characteristics and those of their
diseases are presented in Table 1. 
When analyzing HbF kinetics over time (Figure 1A,
Online Supplementary Figure S1), the first on-treatment time
point with robust HbF induction was at the end of the sec-
ond course of decitabine treatment. Compared to the
median pre-treatment HbF of 0.8%, we observed overall
induction to 1.1% after course 2. The median fold-change
of HbF concentration at the end of the second course of
decitabine treatment as compared to pre-treatment levels
was 1.67 (P=0.088). 
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By grouping patients according to pre-treatment HbF
levels (normal versus elevated) and subsequent HbF levels
(normal versus increased), four different patterns could be
discerned. In patients with normal pre-treatment HbF,
HbF was either induced to levels above the upper limit of
normal (group A, n=11) or remained within the normal
range (group B, n=12); among patients with elevated pre-
treatment levels, HbF either remained elevated also in sub-
sequent measurements (group C, n=13, in most cases after
an initial drop following the first treatment course) or
dropped to normal levels, without subsequent elevation
above the upper limit of normal (group D, n=3). Two
vignettes representative of each of the four different pat-
terns of HbF kinetics are shown in Figure 1B. The number
of treatment courses varied between these four groups:
median numbers were 5, 2, 7 and 3 courses in groups A, B,
C and D, respectively (range: 2-11, 2-6, 2-23, and 2-6
courses, respectively). Consequently, more patients in
groups A and C attained hematologic responses over time,
including complete remission (with suppression of the
abnormal clone in patients with initial cytogenetic abnor-
malities), compared to patients in groups B and D. HbF
levels were elevated in significantly more patients during
treatment (groups A+C: n=24, 61.5%) than prior to treat-
ment (groups C+D: n=16, 41.0%; P=0.033).
Early HbF induction by decitabine has predictive value
for subsequent hematologic stabilization and response
Among patients achieving complete or partial remission
as their best overall response, a median HbF of 1.9%
(1.9% in MDS, 2.0% in AML) was observed at this time
point compared to a median of 0.8% (1.0% and 0.6%,
respectively) in patients not attaining complete or partial
remission (P=0.015) (Figure 1C, Online Supplementary
Figure S2).
Given that robust HbF induction during decitabine
treatment was first observed after two cycles of treatment,
we chose this time point for further analyses regarding the
potential value of HbF induction for predicting subsequent
responses. Using linear regression models and correlation
analyses, we assessed the association between HbF levels
after course 2 of decitabine treatment and responses in the
different hematopoietic lineages after course 4 in all 40
MDS/AML patients (3 patients did not receive more than
2 courses, but had peripheral blood counts available 3
months after course 2: one underwent hematopoietic
stem cell transplantation, one changed to a different study
after course 2, and one received thalidomide and best sup-
portive care at that point). 
Higher HbF levels after two courses were associated with
significantly higher platelet counts after four courses
(rs=0.49, P=0.01) (Figure 2A). As for neutrophil counts, a
trend towards higher counts after course 4 in patients with
elevated HbF levels after course 2 was noted (rs=0.35,
P=0.08) (Figure 2B). A borderline significant association was
also observed between HbF levels after two courses of
treatment and hemoglobin levels after four courses (rs=0.36,
P=0.08) (Figure 2C). Interrogating the potential prognostic
value of HbF induction for bone marrow blast suppression
after four courses in the entire cohort of 21 MDS/AML
patients with available blast counts, an association was
noted (rs=-0.48, P=0.03) (Figure 2D). When looking at MDS
and AML patients separately, the overall results were simi-
lar in both cohorts, particularly for blast suppression (Online
Supplementary Figure S4A-D). Moreover, similar results were
observed when restricting the same kind of analysis to
MDS and AML patients who had received more than four
courses of decitabine (data not shown). 
In patients achieving platelet doubling already after one
course of decitabine, the median HbF after course 2 was
1.9%, versus 0.8% in patients without this platelet
response (P=0.006) (Figure 2E). In contrast, no correlation
was observed between HbF levels and platelet counts
before treatment initiation: rs=-0.13 (P=0.63) in MDS
(n=16) and rs=0.02 (P=0.91) in AML patients (n=36).
Association of HbF induction by decitabine and
survival outcomes in patients with myelodysplastic 
syndrome/acute myeloid leukemia
Overall, progression-free and AML-free survival were
measured from the time of HbF determination after com-
pletion of two courses of decitabine treatment. In the
MDS cohort, overall survival was significantly longer in
the nine patients in whom HbF was elevated above the
upper limit of normal at that time point than in the six
patients with HbF in the normal range: median 22.9 versus
7.3 months, respectively (HR=0.21; 95% CI: 0.05-0.87;
P=0.03) (Figure 3A). Censoring the six patients who had
HbF induction in AML/MDS and outcome prediction
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Table 1. Characteristics of MDS and AML patients and their disease at
baseline.
                                                               MDS                         AML
Age (years; median and range)             74 (66 - 77)                 73 (62 - 82)
Sex                                                                                                                 
Male                                                                    8                                    15
Female                                                                7                                    10
FAB subtype                                                                                                
                                                                             RA: 1                             M1: 4
                                                                          RAEB: 8                           M2: 2
                                                                         RAEB-t: 4                         M4: 5
                                                                        CMMoL: 2                         M5: 1
                                                                                                                   M6: 3
                                                                                                                  N/A: 10
WBC (x 109/L; median and range)      2.4 (0.8 - 18.8)            2.2 (0.5 - 27.1)
ANC (x 109/L; median and range)     0.93 (0.16 - 2.40)          0.33 (0 - 14.09)
Peripheral blood blasts                            1 (0 - 13)                     19 (0 - 96)
(%; median and range)
Bone marrow blasts                                 18 (2 - 30)                   55 (10 - 95)
(%; median and range)
Hb (g/dL; median and range)             8.4 (5.0 - 11.3)            8.7 (5.6 - 12.4)
PLT (x 109/L; median and range)          35 (10 - 151)                34 (7 - 229)
sLDH (U/l; median and range)           235 (102 - 842)          271 (134 - 1276)
Cytogenetics                                                                                                
                                                                        Normal: 3           Intermediate risk: 7
                                                                        Sole 5q-: 1                   Poor risk: 6
                                                                         Sole -7: 1                   < 10 normal 
                                                                                                           metaphases: 4
                                                                       Complex: 6            No metaphases: 1
                                                                 No metaphases: 4                 N/A: 7
MDS: myelodysplastic syndrome; AML: acute myeloid leukemia. RA, refractory ane-
mia; RAEB: refractory anemia with blast excess; RAEB-t: refractory anemia with blast
excess in transformation (i.e. AML according to the World Health Organization classi-
fication); CMMoL: chronic myelomonocytic leukemia. FAB (French-American-British)
subtypes: M1: acute myeloblastic leukemia with minimal maturation; M2: acute
myeloblastic leukemia with maturation; M4: acute myelomonocytic leukemia; M5:
acute monocytic leukemia; M6: acute erythroid leukemia. N/A: not assessed; WBC:
white blood cells; ANC: absolute neutrophil counts; Hb: hemoglobin; PLT: platelets;
sLDH: serum lactate dehydrogenase.
J. Stomper et al.
62 haematologica | 2019; 104(1)
Figure 1. HbF kinetics in patients with myelodysplastic syndrome/acute myeloid leukemia
during treatment with decitabine.  (A) Box plot of HbF values prior to treatment with
decitabine and after each of the first eight treatment courses in patients with myelodysplas-
tic syndrome (n=15) or acute myeloid leukemia (n=25) for whom there was more than one
measurement of HbF level. HbF was measured prior to treatment (= cycle 0) in 39 of these
patients, after courses 1 to 8 (= cycles 1, 2, 3, etc.) in 38, 32, 24, 18, 14, 10, 7, and 9 of
these patients, respectively. Outliers are plotted as individual points, extreme values as
stars. For each of cycles 0, 1, and 3, one extreme value is not displayed in the diagram, and
one outlier is not shown for cycle 2. (B) Two representative vignettes of each of the four
groups of HbF responses to decitabine treatment are shown: initially normal HbF induced to
levels above (group A) or remaining within the normal range during treatment (group B);
already elevated pre-treatment HbF remaining elevated (group C) or decreasing to normal
levels (group D). Shaded areas within the charts indicate values outside the normal range.
The end of each decitabine treatment course is indicated with a numbered arrow. Hb: hemo-
globin; HbF: fetal hemoglobin; PLT: platelets; WBC: white blood cells. (C) Box plot of HbF val-
ues at the end of the second course of decitabine treatment in 32 MDS/AML patients show-
ing higher HbF levels in patients achieving complete or partial remission (CR, PR) as best




undergone hematopoietic stem cell transplantation at the
time of their transplant, this difference lost statistical sig-
nificance (P=0.098) (Online Supplementary Figure S6). The
secondary endpoints, progression-free survival and AML-
free survival were also investigated and showed a trend to
a more favorable outcome for patients with elevated HbF:
the median progression-free survival was 7.7 months ver-
sus 2.4 months (HR=0.32; 95% CI: 0.10-1.10; P=0.07)
(Figure 3B) and the median AML-free survival was 13.1
months versus 7.6 months (HR=0.42; 95% CI: 0.13-1.38;
P=0.15) (Figure 3C).
In the AML cohort, 17 patients had HbF determinations
available after two courses of treatment and could be
included in a survival analysis. There was no significant
difference in overall survival between those with elevated
HbF (n=9) and those with normal HbF (n=8): the median
overall survival was 17.3 and 11.6 months, respectively
(HR=0.68; 95% CI: 0.23-1.96; P=0.47) (Figure 3D). 
Elevated HbF levels are observed in decitabine-treated
patients with myelodysplastic syndrome/acute 
myeloid leukemia with bone marrow blast 
clearance, and decline at relapse
To investigate whether malignant cells or normal,
emerging erythroid precursors synthesize the elevated
HbF in response to HMAs, linear regression analyses were
performed (Figure 4A). This showed an association
between HbF induction after four treatment courses and a
decreasing percentage of blasts at this time point in 17
MDS/AML patients.  
HbF induction in AML/MDS and outcome prediction
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Figure 2. HbF levels after two courses of decitabine treatment are associated with responses of different
hematologic lineages after course 4, and with early platelet doubling.  HbF values after treatment course
2 (x-axis) in patients with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) who received at
least two cycles of decitabine were plotted against (A) platelet counts (n=25) (y-axis), (B) absolute neutrophil
counts (n=25), (C) hemoglobin levels (n=25), and (D) the percentage of bone marrow blasts (n=21), as
determined after course 4. Linear regression equations are represented as lines and were estimated as (A)
platelets=36+41*HbF, (B) absolute neutrophil count=1243+340*HbF, (C) hemoglobin=9.4+0.5*HbF, (D)
percentage bone marrow blasts=25-6*HbF. (E) Box plot demonstrating significantly higher HbF values after
the second course of decitabine treatment in MDS/AML patients who achieved platelet doubling already





Looking in more detail at the subgroup of 18 patients
who received more than four courses of treatment, it was
noted that six attained not only a multilineage hematolog-
ic response but also bone marrow blast clearance.
Interestingly, in all of them HbF levels were, or became,
elevated at the time of remission. In four of these patients,
the complete remission status could be confirmed by cyto-
genetics: chromosomal abnormalities present at baseline
were no longer detectable at that point (cytogenetic remis-
sion; in several of these patients, suppression of the abnor-
mal clone was confirmed by fluorescence in situ hybridiza-
tion). 
Taken together, these analyses strongly suggested that
HbF induction observed after four courses of treatment
occurred preferentially in the emerging non-clonal ery-
throid cells, in which epigenetically silenced beta-globin-
like genes were reactivated by treatment with the HMA.
For seven MDS/AML patients, HbF measurements were
obtained both after the end of decitabine course 2 and at
the time of hematologic relapse. Relative to an elevated
HbF level after course 2 (median 1.9%; range, 1.5-4.6%), a
decrease was observed in all seven patients at the time of
relapse (median 1.1%; range, 0.2-1.9%). In two of these
patients (both of whom had a complex karyotype), the
decline in HbF level preceded the hematologic relapse,
implicating it as a potential early predictor of relapse in a
subgroup of patients. Notably, the initial increase after
course 2 compared to pre-treatment HbF levels (available
for 6 patients: median 1.2%; range, 0.3-3.9%) became
reversed at relapse in five of the six patients (Figure 4B). 
Decitabine triggers an erythroid but not a
megakaryocytic maturation program in
bi-potential myeloid leukemia cells 
To model the effects of decitabine in vitro, two
myeloblastic cell lines (K562, HEL) with bi-lineage differ-
entiation potential were treated with decitabine at non-
toxic concentrations. Striking morphological changes
included polyploidy and cytoplasmic maturation indica-
tive of partial erythroid differentiation (Figure 5A), con-
firmed by benzidine staining in K562 cells: decitabine- and
hemin- but not PMA-treated cells became hemoglobin-
positive (Figure 5B). K562 cells treated with PMA devel-
oped morphological changes indicative of megakaryocytic
differentiation and induction of surface CD41/61 whereas
lack of CD41 detection by FACS analysis after decitabine
J. Stomper et al.
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Figure 3. Elevated HbF after course 2 of decitabine treatment is associated with improved survival in patients with myelodysplastic syndrome.  Kaplan-Meier sur-
vival estimates were determined according to whether HbF after course 2 of decitabine treatment was in the normal range (i.e. 0-1.0% of total hemoglobin) or ele-
vated (i.e. >1.0%). (A) Overall survival of 15 patients with myelodysplastic syndrome (MDS), two in the group with elevated HbF censored at 100 months (still alive
in remission following allografting). (B) Progression-free survival of 15 MDS patients, one in the group with elevated HbF censored (still alive in remission following
allografting). (C) Acute myeloid leukemia (AML)-free survival of 15 MDS patients, one in the group with elevated HbF censored (still alive in remission following allo-
grafting). (D) Overall survival of 17 AML patients, one in the group with elevated HbF censored (still alive in remission following allografting). 
A B
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and hemin indicated absence of megakaryocytic differen-
tiation (Figure 5C). 
Transcriptome profiling by mRNA expression arrays in
K562 cells revealed the greatest similarity between hemin-
and decitabine-treated cells (Figure 6A,B). Notably, tran-
scriptome changes of PMA-treated K562 cells were most
extensive and clustered most distantly from those of all
other treatments (Figure 6A,B). In HEL cells, variable
probes also differed considerably between decitabine and
PMA treatment (Online Supplementary Figures S8 and S9).
Gene ontology analyses of upregulated transcripts consis-
tently identified terms related to erythropoiesis and iron
metabolism among the top regulated transcript groups in
decitabine-treated cells whereas terms related to
megakaryocyte lineage differentiation did not show sig-
nificance (data not shown).
Among the transcripts upregulated by decitabine, almost
all major globin genes could be identified (Figure 6C).
Decitabine-treated K562 showed a >7-fold induction of
alpha-1/alpha-2-globin transcription whereas PMA treat-
ment did not alter alpha-globin transcription. Gamma-glo-
bin transcription was induced by all three treatments, with
decitabine exhibiting the most pronounced effect. A strong
induction was also noted for zeta-globin transcription
upon decitabine and hemin, but not PMA, treatment.
Similar patterns were noted for HEL (data not shown). 
To prove induction of functionally competent HbF mol-
ecules in K562 cells by decitabine treatment, we quantified
hemoglobin tetramers by cation-exchange chromatogra-
phy. In two independent experiments, a reproducible time-
and dose-dependent (albeit modest) induction of HbF
tetramers was noted (Figure 6D).  
Decitabine-induced globin transcription in K562 cells
is associated with GATA1 gene demethylation and
upregulation
To determine whether transcriptional upregulation of
both the hemoglobin gamma 1 (HBG1) and 2 (HBG2) gene
was a consequence of direct DNA methylation changes at
the locus control region or at direct upstream regulatory
regions of both genes, DNA methylation was assessed
globally by methyl-CpG immunoprecipitation, as previ-
ously described.24 No enrichment could be demonstrated
in untreated or in decitabine-treated K562 cells, indicating
absence or only very low levels of DNA methylation at
the HBG1 and HBG2 promoter and at the locus control
region (Online Supplementary Figure S10). The gamma-glo-
bin locus is known to be devoid of a CpG island,25 and was
shown to be unmethylated when selected CpG sites were
interrogated for their methylation status by using methy-
lation-sensitive restriction enzymes.26
The presence of activating H3K4me3 and H3K9ac his-
tone marks (from K562 data sets of the ENCODE consor-
tium27) and absence of the repressive mark H3K27me3
(data not shown) indicated that transcriptional activity was
already present in untreated cells at both loci, which could
be demonstrated by the elevated HBG1/HBG2 probe
intensity in the mRNA expression array data (Figure 6C).
GATA1 has been identified as a key regulatory factor
which binds prominently to the locus control region of the
beta-globin locus (Online Supplementary Figure S10). In
order to understand how HMA treatment might con-
tribute to the transcriptional upregulation of HBG1 and
HBG2 without altering pre-existing low levels of local
DNA methylation in K562 cells, we assessed DNA methy-
lation at the GATA1 gene locus. Upon decitabine treat-
ment, DNA methylation was substantially reduced in
K562 cells at the GATA1 promoter region and at an
upstream regulatory region (Figure 7A). Western blot
analysis of K562 cells after 3 days of decitabine treatment
demonstrated a dose-dependent, 2- to 3-fold upregulation
of GATA1 protein at day 3 (Figure 7B). After 6 days of
treatment, this effect was less pronounced. In contrast,
PMA treatment strongly repressed GATA1 expression, an
effect only modestly antagonized by decitabine. 
Discussion 
Clinically meaningful pharmacological induction of
developmentally silenced HbF gene expression9,28 is a
prime example of what has been termed epigenetic thera-
py. However, the broad clinical application of this
approach in hemoglobinopathies has been limited by con-
cerns of long-term mutagenic effects in these chronic dis-
orders. The recent advent of DNA-hypomethylating treat-
ment using azanucleoside DNA methyltransferase
HbF induction in AML/MDS and outcome prediction
haematologica | 2019; 104(1) 65
A
B
Figure 4. Induced HbF seems
to be preferentially derived
from non-malignant ery-
throid cells.  (A) Linear
regression model showing
the association between HbF
induction after four courses
of treatment and a decreas-
ing percentage of blasts at




Comparison of HbF levels
prior to treatment, after
course 2 of decitabine, and
at relapse. Three MDS and
three AML patients had HbF
measurements available at
all three time points. In five of
the six patients, the initial
increase in HbF after course
2 compared to pre-treatment
levels became reversed at
relapse. In four of these five
patients, the level of HbF at
relapse was even lower than
that at the start of treatment.
J. Stomper et al.
66 haematologica | 2019; 104(1)
A B
C
Figure 5. Decitabine induces erythroid differentiation and hemoglobin synthesis in K562 and HEL early myeloid progenitor cells. (A) K562 and HEL cells were treat-
ed with three 24 h pulses of 100 nM decitabine. Morphological signs of erythroid differentiation upon decitabine (DAC) treatment were determined by cytospin prepa-
ration and May-Grünwald staining. (B) Hemoglobin synthesis in K562 cells was determined by benzidine staining. Cells were treated with DAC  (three 24 h pulses,
100 nM), hemin (50 mM for 48 h), phorbol 12-myristate 13-acetate (PMA, 5 nM) and a combination of DAC and PMA at these concentrations. For each experimental
point, 300 cells were counted, with blue cells being considered hemoglobin-positive. (C) Flow cytometry analysis of CD41/61 surface markers (highly specific for
megakaryocytic differentiation) showed differentiation with PMA but not DAC treatment.
Figure 6. Decitabine treatment induces
an erythroid transcriptome signature,
globin chain expression and fetal
hemoglobin assembly in K562 cells.
(A) Transcriptome analyses were per-
formed in K562 cells upon treatment
(as described in the legend to Figure 5)
with decitabine (DAC, 100 nM), hemin
(25 and 50 mM), phorbol 12-myristate
13-acetate PMA (PMA, 5 nM) or without
treatment (untreated #1 – no treat-
ment, untreated #2 – phosphate-
buffered saline as a vehicle control)
using mRNA microarrays (HG-U133plus
2.0 gene chip, Affymetrix). The most
variable probes (relative standard devi-
ation among all samples ≥2) are dis-
played as a heatmap with unsupervised
hierarchical clustering (Euclidian dis-
tance). (B) Venn diagram displaying
unique and shared ≥2-fold upregulated
and ≥2-fold downregulated probes
between the three treatments in K562
cells. (C) Relative mean probe intensi-
ties representing expression of globin
chain transcripts: HBA1/HBA2, alpha-
globin 1 and 2; HBB, beta-globin;
HBG1/HBG2, gamma-globin 1 (G-
gamma) and 2 (A-gamma); HBD, delta-
globin; HBE1, epsilon-globin 1; HBM,
mu-globin; HBQ1, theta-globin, HBZ,
zeta-globin) in untreated K562 cells
and upon DAC, hemin and PMA treat-
ment, respectively. (D) Increase of func-
tional HbF tetramers determined by
high-performance liquid chromatogra-
phy as a fraction of total cellular protein
upon DAC treatment (50 and 100 nM)
after 72 and 144 h, respectively. Note
the time-dependent incremental rise in
HbF (dose-dependent at 72 h).
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inhibitors in MDS and AML has re-kindled an interest in
HbF regulation in vivo. Specifically, we and others have
recently described HbF induction in patients with MDS or
AML receiving the DNA methyltransferase inhibitors
azacitidine or decitabine.14-16,29
Since HMAs have to be administered over repeated
treatment cycles in order to induce responses (which then
occur only in about half of the patients), early markers
predicting subsequent outcome are urgently needed in
order to better advise patients whether to continue HMA
treatment or switch to alternative therapy.
In order to investigate induction of HbF as a potential
predictor of outcome, we chose the time point at the end
of two courses of decitabine treatment, i.e. approximately
12 weeks after starting treatment, as the most meaningful:
it disclosed the first robust HbF induction (Figure 1A), and
was still early enough to be useful for predicting later out-
come (whereas information at later time points would be
a "self-fulfilling prophecy" regarding response and sur-
vival). Indeed, higher HbF at this time point was associat-
ed with overall objective responses and, particularly in
MDS patients, with improvement of the different
hematopoietic lineages after four courses of treatment.
Notably, MDS patients with elevated HbF after two
course of decitabine treatment had longer overall survival
and trends to longer progression-free and AML-free sur-
vival. For AML patients, the median overall survival was
also nominally longer in this group, but the difference was
not statistically significant (possibly because at that time
point, half of the AML patients had already died). Time
point optimization in AML patients therefore appears nec-
essary, particularly in view of the presently used
decitabine treatment schedules of drug administration 5 or
10 days every 4 weeks. It was encouraging to note that
higher HbF levels after two courses of treatment were
associated with platelet doubling after one course, one of
the few established early dynamic predictors of outcome
with HMAs.30,31
In order to assess whether these results are applicable in
clinical practice, and given the fact that a different
decitabine dose is commonly used in MDS and AML
patients at present, these results warrant validation in a
larger cohort of patients treated with current dosing
schemes. For this purpose, serial measurements of HbF
have recently been performed in decitabine-treated AML
patients randomized within the "inDACtion versus induc-
tion" Intergroup AML trial 1301 of the EORTC Leukemia
Group (NCT02172872).
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Figure 7. Decitabine induces gene demethylation and expression of the erythroid-specific transcription factor GATA1 in K562 cells.  (A) Schematic representation
of the GATA1 gene locus. The GATA1 gene is depicted as a black line from 5’ (left) to 3’ (right) with exons represented as boxes. CpG density (CpGs) is indicated by
vertical bars. Transcription factor (TF) binding sites were determined through combined TF chromatin immunoprecipitation sequencing (ChIP-seq) experiments from
different tissues/cell lines published by the ENCODE consortium. Likewise, activating histone marks H3K9ac and H3K4me3 are taken from ChIPseq experiments in
untreated K562 cells which were published and made publicly available from the ENCODE consortium. DNA methylation was assessed by enrichment through methyl-
CpG immunoprecipitation sequencing experiments in untreated K562 cells (K562 untr.) and in K562 cells treated with decitabine (K562 DAC). (B) K562 cells were
treated with three 24 h pulses of 100 nM or 200 nM decitabine and harvested on days 3 and 6. PMA 5 nM was added to the culture media for the final 48 h.
Immunoblotting of whole cell lysates with rat anti-GATA1. Immunoblotting with mouse anti-beta-actin was performed to control for lane loading. 
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With the perspective of exploiting HbF as a potential
biomarker for response to HMA therapy, it might be used
for selecting a cohort of MDS/AML patients who exhibit
a significant increase in HbF after two cycles of decitabine
treatment as candidates for a future clinical trial. Such a
trial could have the objective to increase the effectiveness
of HMA therapy by dose-schedule modifications and/or
in combination with other epigenetic or other agents to
increase the duration of response. 
In practical terms, HbF measurement during HMA
treatment needs to be compared in different laboratories
(at this study’s central laboratory, HPLC quantification of
different rare Hb species, including HbF, has been opti-
mized for linear quantification also of smaller amounts).
However, baseline HbF is also a promising predictor of
HMA response and outcome, as recently demonstrated in
the same cohorts of patients.16 At first sight it appears
counter-intuitive that pre-treatment high expression may
be biologically linked to outcome. However, as already
discussed,16 elevated pre-treatment HbF levels may reflect
incomplete silencing by methylation (and possibly other
epigenetic mechanisms) of the gamma-globin locus, pro-
viding a potential surrogate marker for higher de novo sen-
sitivity to HMAs. Interestingly, Cross et al.32 made a simi-
lar observation studying long interspersed element
(LINE)-1 methylation in AML patients treated with azac-
itidine: lower LINE-1 methylation prior to treatment, but
not early hypomethylation under treatment, predicted
hematologic response to this in vivo hypomethylation. 
What is the cellular source of HbF during the different
treatment phases in MDS and AML patients receiving
HMAs? In untreated MDS patients clonal erythroid pro-
genitors,33 and in untreated AML patients residual normal,
non-clonal erythroid progenitors may be the source of
HbF-containing erythrocytes.34 In contrast, in patients
attaining a complete or cytogenetic remission, it is more
likely that the target cell of HMAs (presumably achieving
hypomethylation and transcriptional de-repression of the
beta-globin-like gene locus) is part of the non-clonal ery-
thropoiesis, as in patients with solid tumors who show
HbF induction during HMA treatment.10,11 The increase in
platelet count after decitabine treatment indicates that
decitabine reduced or eliminated the suppressive action
of the malignant cells on normal hematopoiesis, with
subsequent expansion of normal hematopoietic stem
cells, which undergo differentiation. At the time of hema-
tologic relapse, the decline in HbF levels might be due to
the recurrence of the malignant clone. This contrasts with
the model of increased HbF levels in juvenile
myelomonocytic leukemia resulting from epigenetic dys-
regulation of beta-like-globin genes in leukemic cells.35
Serial immunohistochemical bone marrow studies for
HbF expression in MDS/AML patients receiving HMAs
are warranted to determine the cell of origin of HbF pro-
duction during the different phases of treatment. 
Modeling the effects of decitabine on the erythroid ver-
sus megakaryocytic lineage in two bi-potential myeloid
cell lines, activation of an erythroid but not megakary-
ocytic gene expression program was observed, including
induction of gamma-globin expression and induction,
albeit modest, of HbF tetramer formation. We could
demonstrate that decitabine treatment regulated many of
the genes also regulated by hemin (including mRNA for
erythroid-specific transcription factors and beta-like-glo-
bin genes), and induced GATA1 at the protein level, con-
comitantly with demethylation at several cis-regulatory
regions known to be important for the regulation of this
gene.36,37 Notably, the overlap between the transcriptome
changes induced by decitabine versus hemin was more
marked in the downregulated genes compared to the
upregulated ones. Despite demonstrating GATA1 gene
demethylation following decitabine treatment, we are
unable to conclude that GATA1 induction is a direct con-
sequence of demethylation or is occurring during ery-
throid differentiation triggered via other factors. Here, a
similar DNA methylation analysis of K562 cells treated
with hemin instead of decitabine would address this
"cause or consequence" question.
Taken together, the cell line experiments suggested that
increased levels of HbF can also occur because of the
effects of decitabine on malignant cells of the erythroid
lineage. However, since a cell line is not a good model of
the normal functional hematopoietic hierarchy, no con-
clusion can be drawn as to why erythroid rather than
megakaryocytic differentiation was observed. 
Is there a clinical relevance of induction of HbF beyond
HMA treatment? Very recently, in a preclinical study a
novel, specific inhibitor of histone deacetylase 1/2 also
demonstrated a strong propensity to induce HbF.38
Furthermore, it is well established that inhibitors of the
first histone lysine-specific demethylase (LSD)1, includ-
ing novel, highly specific LSD1/KDM1A inhibitors such
as RN-1, are able to reactivate a silenced beta-globin-like
gene locus.39 Furthermore, UNC0638, a selective inhibitor
of the histone methyltransferases EHMT1 and EHM2,
has the ability to induce HbF expression, and this potency
is enhanced when the drug is combined with decitabine
or the histone deacetylase inhibitor entinostat.40 Very
recently, pomalidomide was also shown to be able to
induce HbF in patients with multiple myeloma.41 Thus,
serial HbF measurements in these different clinical set-
tings may be interesting in order to determine whether
the kinetics of this parameter is predictive of treatment
response.
In conclusion, the technically simple test of assaying
HbF levels warrants further prospective studies since the
time to best response in patients treated with HMAs is
often in the range of 4-6 months. Earlier tailoring of treat-
ment is, therefore, highly desirable. It will be of interest
to determine the predictive value of HbF levels compared
to other, already established predictors of HMA response
such as hematologic parameters, genetic and DNA
methylation markers.
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